Cytokine profiles in the aqueous humor following brolucizumab administration for exudative age-related macular degeneration

Graefes Arch Clin Exp Ophthalmol. 2023 Sep;261(9):2465-2476. doi: 10.1007/s00417-023-06038-9. Epub 2023 Mar 31.

Abstract

Purpose: To identify the inflammatory cytokine profile in the aqueous humor (AH) of patients with intraocular inflammation (IOI) after intravitreal administration of brolucizumab (IVBr) for neovascular age-related macular degeneration.

Methods: Eight eyes from seven patients with IOI after initial IVBr (IVBrIOI +) were enrolled. Sixteen eyes from 16 patients without IOI after IVBr (IVBrIOI -) and aflibercept (IVA) were used as controls. AH samples were analyzed using a multiplex immunoassay.

Results: C-C motif chemokine ligand (CCL)2, C-X-C motif chemokine ligand (CXCL)1, CXCL10, CXCL13, interleukin (IL)-6, IL-8, IL-10, matrix metalloproteinase (MMP)-1, MMP-9, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), intercellular adhesion molecule (ICAM)-1, E-selectin, and P-selectin levels were significantly higher in IVBrIOI + than in IVBrIOI - and IVA. Vascular endothelial growth factor (VEGF) was significantly lower in IVBrIOI - compared to that in IVBrIOI + and IVA. In the IVBrIOI + group, there were significant correlations between CCL2, CXCL1, IL-6, IL-8, IL-10, G-CSF, GM-CSF, ICAM-1, and E-selectin, which also exhibited significant correlations in the IVBrIOI - group.

Conclusion: The number of inflammatory cytokines increases during IOI, which is associated with type IV hypersensitivity and vascular inflammation. Some cytokines exhibit correlations even in non-inflamed eyes, indicating a subclinical response to IVBr.

Keywords: Age-related macular degeneration; Brolucizumab; Cytokines; Intraocular inflammation; Retinal vasculitis; Vascular endothelial growth factor.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Aqueous Humor / metabolism
  • Cytokines / metabolism
  • E-Selectin / metabolism
  • E-Selectin / therapeutic use
  • Granulocyte Colony-Stimulating Factor / metabolism
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Granulocyte-Macrophage Colony-Stimulating Factor* / metabolism
  • Granulocyte-Macrophage Colony-Stimulating Factor* / therapeutic use
  • Humans
  • Inflammation / metabolism
  • Interleukin-10
  • Interleukin-6
  • Interleukin-8 / metabolism
  • Intravitreal Injections
  • Ligands
  • Macular Degeneration* / drug therapy
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • brolucizumab
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Interleukin-10
  • E-Selectin
  • Interleukin-8
  • Vascular Endothelial Growth Factor A
  • Ligands
  • Cytokines
  • Interleukin-6
  • Granulocyte Colony-Stimulating Factor
  • Angiogenesis Inhibitors